Shaogang Huang

Dr. Shaogang Huang

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
FYFeng-Yan Yu
Feng-Yan Yu
SHShaogang Huang
Shaogang Huang
HZHai-Yan Zhang
Hai-Yan Zhang
HYHua Ye
Hua Ye
HCHong-Gang Chi
Hong-Gang Chi
XZXue-Bao Zheng
Xue-Bao Zheng
Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis

23 December 2024 in eGastroenterology
Verified
Journal Article
Open access
PDF file
ZYZhi-Ning Ye
Zhi-Ning Ye
GEGuy D Eslick
Guy D Eslick
SHShaogang Huang
Shaogang Huang
XHXing-Xiang He
Xing-Xiang He
The sustained increase in antibiotic resistance leads to a declining trend in the eradication rate of Helicobacter pylori (H. pylori) infection with antibiotic-based eradication regimens. Administration of a single probiotic shows limited efficacy in eradicating H. pylori infection. This review indicates that faecal microbiota transplantation (FMT), a novel therapeutic approach, either as a monotherapy or adjunctive therapy, exhibits beneficial effects in terms of the eradication of H. pylori infection and the prevention of adverse events. The role of FMT in H. pylori eradication may be associated directly or indirectly with some therapeutic constituents within the faecal suspension, including bacteria, viruses, antimicrobial peptides and metabolites. In addition, variations in donor selection, faecal suspension preparation and delivery methods are believed to be the main factors determining the effectiveness of FMT for the treatment of H. pylori infection. Future research should refine the operational procedures of FMT to achieve optimal efficacy for H. pylori infection and explore the mechanisms by which FMT acts against H. pylori.

1 April 2015
Verified
Journal Article
Closed access
FYFeng-Yan Yu
Feng-Yan Yu
SHShaogang Huang
Shaogang Huang
HZHai-Yan Zhang
Hai-Yan Zhang
HCHong-Gang Chi
Hong-Gang Chi
YZYing Zou
Ying Zou
XZXue-Bao Zheng
Xue-Bao Zheng

11 July 2018 in Trials
Verified
Journal Article
Open access
QLQian Li
Qian Li
BZBeiping Zhang
Beiping Zhang
SHShaogang Huang
Shaogang Huang
WOWenwei Ouyang
Wenwei Ouyang
JXJian-Hui Xie
Jian-Hui Xie
XYXiao-Bo Yang
Xiao-Bo Yang
Background: Irritable bowel syndrome (IBS) is a chronic, recurring condition, prevalent in the general population. Current medication treatments usually leave patients undertreated. Nowadays, Chinese medicine (CM) is being considered as a promising treatment approach for IBS. However, due to methodological limitations, there is no strong evidence to support CM. Although IBS relapses are common, the relapse assessment has always been neglected in CM study designs. Meanwhile, in clinical practice and studies, it has been found that certain CM formulas can only benefit certain kinds of patients. Discovering what population and illness characteristics likely respond to outcomes may help improve the effectiveness of CM. The aims of this study are to evaluate the efficacy and safety of Tiao-Chang Ke-Min (TCKM) granules for IBS, especially in reducing IBS symptoms' relapse, by a highquality randomized controlled trial and then to optimize the indication of the TCKM granules. Methods/design: This is a parallel-group, randomized, double-blind, placebo-controlled trial embedded with outcome predictive factors. Eligible patients with diarrhea-predominant IBS will be randomized into either a TCKM granule group or a placebo group. Patients from both groups will receive health education. The treatment duration is 4 weeks and the follow-up is 12 weeks. The primary outcome is global improvement measured with adequate relief (AR). The second outcome measures include time until relief, time until first relapse, total relapse times, long-term effectiveness, individual symptoms, IBS-Symptom Severity Score (IBS-SSS), IBS-Quality of Life Questionnaire (IBS-QOL), and Hospital Anxiety and Depression Scale (HADS). Predictive factors associated with patient and illness characteristics have been widely collected. These factors will be embedded in this trial for further identification. Discussion: This trial may provide high-quality evidence on the efficacy and safety of TCKM granules for IBS and a more accurate indication. Importantly, this trial will provide a new research method for improving the therapeutic effects of CM for clinicians and researchers. To address IBS relapse assessment, a series of special definitions of relapse incidents has been made for this trial.